Palisade Bio (PALI) Financials

Palisade Bio logo
$1.01 -0.02 (-1.94%)
Closing price 04:00 PM Eastern
Extended Trading
$1.01 +0.00 (+0.50%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Palisade Bio

Annual Income Statements for Palisade Bio

This table shows Palisade Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-21 -21 -16 -4.92 -8.35 -10 -27 -15 -12 0.00 0.00
Consolidated Net Income / (Loss)
-21 -21 -16 -4.92 -8.35 -10 -27 -14 -12 -14 -17
Net Income / (Loss) Continuing Operations
-21 -21 -16 -4.92 -8.35 -10 -27 -14 -12 -14 -17
Total Pre-Tax Income
-21 -21 -16 -4.92 -8.35 -10 -27 -14 -12 -14 -17
Total Operating Income
-19 -21 -13 -8.26 -8.63 -9.30 -42 -16 -13 -15 -18
Total Gross Profit
0.01 0.02 0.26 0.26 0.02 0.00 0.00 0.00 0.25 0.00 0.00
Total Revenue
0.01 0.02 0.26 0.26 0.02 0.00 0.00 0.00 0.25 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
19 21 14 8.52 8.65 9.30 42 16 13 15 18
Selling, General & Admin Expense
6.53 7.50 5.47 4.56 4.59 6.20 9.31 8.76 6.20 5.80 7.86
Research & Development Expense
13 13 8.10 3.96 4.06 3.10 33 6.55 6.89 9.06 10
Total Other Income / (Expense), net
-1.75 -0.44 -2.36 3.34 0.28 -1.03 15 1.46 0.77 0.42 1.28
Interest Expense
1.82 1.14 0.16 0.01 0.01 0.24 2.12 0.01 0.02 0.01 0.01
Other Income / (Expense), net
-0.00 0.64 -2.27 3.27 0.22 -0.79 17 1.47 0.79 0.43 1.29
Basic Earnings per Share
($2.99) ($2.53) ($1.20) ($7.54) ($3.80) ($3.72) ($142.95) ($16.53) ($27.01) ($10.19) ($0.30)
Weighted Average Basic Shares Outstanding
6.99M 8.35M 13.06M 653.22K 2.20M 2.77M 186.20K 880.31K 456.01K 1.42M 55.67M
Diluted Earnings per Share
($2.99) ($2.53) ($1.20) ($7.54) ($3.80) ($3.72) ($169.74) ($16.53) ($27.01) ($10.19) ($0.30)
Weighted Average Diluted Shares Outstanding
6.99M 8.35M 13.06M 653.22K 2.20M 2.77M 186.96K 880.31K 456.01K 1.42M 55.67M
Weighted Average Basic & Diluted Shares Outstanding
6.99M 8.35M 13.06M 653.22K 2.20M 13.87M 18.23M 4.50M 12.77M 4.40M 165.88M

Quarterly Income Statements for Palisade Bio

This table shows Palisade Bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-3.53 -4.08 -3.49 11 -2.23 -2.78 -2.87 7.88 -9.60 -11 -15
Consolidated Net Income / (Loss)
-3.53 -4.08 -3.49 -3.34 -2.23 -2.78 -2.87 -8.90 -9.60 -11 -15
Net Income / (Loss) Continuing Operations
-3.53 -4.08 -3.49 -3.34 -2.23 -2.78 -2.86 -8.90 -9.60 -11 -15
Total Pre-Tax Income
-3.53 -4.08 -3.49 -3.34 -2.23 -2.78 -2.86 -8.90 -9.60 -11 -15
Total Operating Income
-3.67 -4.21 -3.59 -3.38 -2.31 -2.84 -2.92 -9.98 -11 -12 -16
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.50 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.50 0.00
Operating Revenue
- - - - - 0.00 0.00 - - 0.50 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
3.67 4.21 3.59 3.38 2.31 2.84 2.92 9.98 11 12 16
Selling, General & Admin Expense
1.46 1.58 1.46 1.30 1.36 1.17 1.53 3.81 4.35 4.80 5.12
Research & Development Expense
2.21 2.63 2.14 2.08 0.95 1.68 1.39 6.17 6.40 7.40 11
Total Other Income / (Expense), net
0.15 0.13 0.11 0.04 0.08 0.06 0.05 1.08 1.15 1.12 1.08
Other Income / (Expense), net
0.15 0.13 0.11 0.04 0.08 0.06 0.06 1.08 1.15 1.12 1.08
Basic Earnings per Share
($4.59) ($3.32) ($2.32) $7.83 ($0.47) ($0.58) ($0.38) $0.14 ($0.05) ($0.05) ($0.07)
Weighted Average Basic Shares Outstanding
768.14K 1.23M 1.50M 1.42M 4.80M 4.80M 7.47M 55.67M 209.66M 211.38M 212.03M
Diluted Earnings per Share
($4.59) ($3.32) ($2.32) $7.83 ($0.47) ($0.58) ($0.38) $0.14 ($0.05) ($0.05) ($0.07)
Weighted Average Diluted Shares Outstanding
768.14K 1.23M 1.50M 1.42M 4.80M 4.80M 7.47M 55.67M 209.66M 211.38M 212.03M
Weighted Average Basic & Diluted Shares Outstanding
937.56K 1.18M 1.33M 4.40M 4.80M 9.12M 149.00M 165.88M 173.58M 174.27M 179.28M

Annual Cash Flow Statements for Palisade Bio

This table details how cash moves in and out of Palisade Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-7.80 10 -8.52 -0.89 -0.67 -2.88 9.78 1.89 0.05 -2.61 124
Net Cash From Operating Activities
-19 -16 -13 -7.69 -7.26 -4.77 -15 -13 -11 -12 -11
Net Cash From Continuing Operating Activities
-19 -16 -13 -7.69 -7.26 -4.77 -15 -13 -11 -12 -11
Net Income / (Loss) Continuing Operations
-21 -21 -16 -4.92 -8.35 -10 -27 -14 -12 -14 -17
Consolidated Net Income / (Loss)
-21 -21 -16 -4.92 -8.35 -10 -27 -14 -12 -14 -17
Depreciation Expense
0.35 0.34 0.29 0.19 0.14 0.00 0.00 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income
2.95 3.26 4.05 -2.62 0.78 3.16 17 -0.27 0.77 0.73 4.26
Changes in Operating Assets and Liabilities, net
-2.20 1.51 -2.15 -0.33 0.17 2.39 -4.78 1.17 0.40 1.51 1.67
Net Cash From Investing Activities
7.25 2.36 -0.09 5.00 0.00 -0.01 -0.05 -0.01 -0.00 0.00 0.00
Net Cash From Continuing Investing Activities
7.25 2.36 -0.09 5.00 0.00 -0.01 -0.05 -0.01 -0.00 0.00 0.00
Purchase of Property, Plant & Equipment
-0.18 -0.10 -0.01 - - -0.01 0.00 -0.01 -0.00 0.00 0.00
Net Cash From Financing Activities
3.89 24 4.99 1.81 6.59 1.89 25 15 11 9.58 134
Net Cash From Continuing Financing Activities
3.89 24 4.99 1.81 6.59 1.89 25 15 11 9.58 134
Repayment of Debt
-1.27 -4.69 -4.09 -0.36 -0.38 -0.11 -1.58 -0.79 -0.39 -0.77 -0.82
Repurchase of Common Equity
-0.05 - - - - 0.00 -0.07 -0.63 -0.62 -0.58 -0.62
Issuance of Common Equity
- - - - 6.55 1.18 5.31 14 9.44 8.45 128
Other Financing Activities, net
-0.80 - - 0.00 0.00 - - 2.27 2.76 2.48 7.64
Cash Interest Paid
0.95 0.99 0.12 0.01 0.01 0.06 0.06 0.01 0.01 0.01 0.01

Quarterly Cash Flow Statements for Palisade Bio

This table details how cash moves in and out of Palisade Bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-1.16 0.08 -3.31 1.78 -2.59 -1.81 -0.19 128 -0.76 -7.46 -12
Net Cash From Operating Activities
-3.18 -3.50 -3.13 -2.38 -2.33 -1.82 -3.55 -3.14 -3.89 -7.60 -12
Net Cash From Continuing Operating Activities
-3.18 -3.50 -3.13 -2.38 -2.33 -1.82 -3.55 -3.14 -3.89 -7.60 -12
Net Income / (Loss) Continuing Operations
-3.53 -4.08 -3.49 -3.34 -2.23 -2.78 -2.87 -8.90 -9.60 -11 -15
Consolidated Net Income / (Loss)
-3.53 -4.08 -3.49 -3.34 -2.23 -2.78 -2.87 -8.90 -9.60 -11 -15
Non-Cash Adjustments To Reconcile Net Income
0.12 0.44 -0.02 0.19 0.10 0.10 0.42 3.64 4.30 4.77 5.07
Changes in Operating Assets and Liabilities, net
0.22 0.14 0.37 0.77 -0.20 0.87 -1.11 2.11 1.41 -1.80 -2.21
Net Cash From Financing Activities
2.02 3.58 -0.18 4.16 -0.26 0.00 3.36 131 3.13 0.15 0.20
Net Cash From Continuing Financing Activities
2.02 3.58 -0.18 4.16 -0.26 0.00 3.36 131 3.13 0.15 0.20
Issuance of Common Equity
- - - 4.44 0.00 - - 128 3.25 0.02 0.20

Annual Balance Sheets for Palisade Bio

This table presents Palisade Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
15 23 14 7.68 6.58 3.02 13 16 14 11 134
Total Current Assets
13 21 12 6.51 5.65 0.90 12 15 13 10 134
Cash & Equivalents
4.72 15 6.67 5.79 5.11 0.71 10 12 12 9.82 133
Prepaid Expenses
1.16 0.65 0.40 0.36 0.51 0.12 1.01 2.35 0.90 0.67 0.84
Plant, Property, & Equipment, net
0.34 0.27 0.17 0.09 0.04 0.01 0.00 0.01 0.01 0.00 0.00
Total Noncurrent Assets
1.18 1.43 1.26 1.09 0.90 2.12 1.00 1.02 0.71 0.38 0.12
Other Noncurrent Operating Assets
0.07 0.02 0.01 0.02 0.23 2.12 1.00 1.02 0.71 0.38 0.12
Total Liabilities & Shareholders' Equity
15 23 14 7.68 6.58 3.02 13 16 14 11 134
Total Liabilities
9.98 11 5.37 1.63 1.46 10 5.15 3.28 2.74 3.39 4.96
Total Current Liabilities
6.43 7.33 1.51 1.05 1.22 8.08 2.50 3.01 2.59 3.24 4.64
Short-Term Debt
4.55 3.71 - - - 0.58 - 0.09 0.16 0.08 0.07
Accounts Payable
1.46 2.34 0.88 0.83 0.82 2.54 1.32 1.76 0.70 1.11 0.77
Accrued Expenses
0.16 0.85 0.42 0.00 0.14 2.74 0.46 0.57 0.83 1.24 2.19
Current Employee Benefit Liabilities
- - - - - 1.59 0.51 0.49 0.78 0.72 1.30
Other Current Liabilities
0.26 0.43 0.22 0.22 0.26 0.64 0.20 0.11 0.12 0.09 0.31
Total Noncurrent Liabilities
3.56 3.94 3.85 0.58 0.23 2.04 2.65 0.27 0.15 0.15 0.33
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
4.97 11 8.52 6.05 5.13 -17 7.37 12 11 7.49 129
Total Preferred & Common Equity
4.97 11 8.52 6.05 5.13 -17 7.37 12 11 7.49 129
Preferred Stock
0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
4.97 11 8.51 6.04 5.12 -17 7.36 12 11 7.49 129
Common Stock
177 204 217 220 227 51 102 122 133 143 282
Retained Earnings
-172 -193 -209 -214 -222 -68 -95 -109 -122 -136 -153

Quarterly Balance Sheets for Palisade Bio

This table presents Palisade Bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
17 13 13 9.34 8.19 6.67 6.97 133 127 119
Total Current Assets
16 12 12 8.87 7.89 6.45 6.83 133 127 117
Cash & Equivalents
15 11 11 8.04 7.23 5.42 5.23 133 125 114
Prepaid Expenses
0.95 0.74 0.96 0.83 0.66 1.03 1.60 0.62 1.59 3.86
Plant, Property, & Equipment, net
0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.79 0.63 0.56 0.46 0.30 0.22 0.15 0.07 0.06 1.07
Other Noncurrent Operating Assets
0.79 0.63 0.56 0.46 0.30 0.22 0.15 0.07 0.06 1.07
Total Liabilities & Shareholders' Equity
17 13 13 9.34 8.19 6.67 6.97 133 127 119
Total Liabilities
2.99 2.59 2.92 2.73 2.86 4.05 3.76 5.95 5.57 6.11
Total Current Liabilities
2.65 2.47 2.84 2.68 2.78 3.97 3.48 5.62 5.25 5.83
Short-Term Debt
0.26 0.00 0.35 0.24 0.00 0.31 0.21 0.00 0.00 0.00
Accounts Payable
0.95 0.46 0.51 0.37 0.75 1.37 1.43 2.70 1.84 1.45
Accrued Expenses
0.79 1.67 1.56 1.51 1.86 2.07 1.22 2.80 3.14 3.61
Current Employee Benefit Liabilities
0.53 0.21 0.29 0.45 0.12 0.19 0.62 0.12 0.28 0.77
Other Current Liabilities
0.12 0.13 0.13 0.12 0.06 0.02 0.00 0.00 0.00 0.00
Total Noncurrent Liabilities
0.34 0.12 0.09 0.05 0.08 0.08 0.28 0.33 0.32 0.28
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
14 10 9.95 6.61 5.33 2.62 3.21 127 122 112
Total Preferred & Common Equity
14 10 9.95 6.61 5.33 2.62 3.21 127 122 112
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
14 10 9.95 6.61 5.33 2.62 3.21 127 122 112
Common Stock
133 135 139 139 144 144 147 290 295 300
Retained Earnings
-119 -125 -129 -133 -138 -141 -144 -162 -173 -188

Annual Metrics And Ratios for Palisade Bio

This table displays calculated financial ratios and metrics derived from Palisade Bio's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
91,786,290.00 114,859,175.00 15,146,027.00 18,205,060.00 3,866,457.00 17,295,703.00 13,574,049.00 77,080,169.00 9,217,129.00 1,329,516.00 149,003,210.00
DEI Adjusted Shares Outstanding
20,397.00 25,524.00 3,366.00 4,046.00 859.00 3,843.00 18,099.00 102,774.00 614,475.00 1,329,516.00 149,003,210.00
DEI Earnings Per Adjusted Shares Outstanding
-1,024.85 -825.68 -4,654.18 -1,217.16 -9,722.53 -2,685.92 -1,470.58 -141.55 -20.04 0.00 0.00
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-44.69% 55.96% 1,500.39% 0.00% -94.08% -100.00% 0.00% 0.00% 0.00% -100.00% 0.00%
EBITDA Growth
7.76% -7.61% 21.13% 68.45% -72.06% -21.98% -142.91% 41.85% 13.78% -17.44% -16.26%
EBIT Growth
7.14% -4.36% 22.08% 67.96% -68.54% -19.93% -142.86% 41.84% 13.77% -17.43% -16.26%
NOPAT Growth
-9.87% -7.73% 35.52% 37.93% -4.51% -7.71% -350.19% 62.44% 16.86% -13.69% -21.52%
Net Income Growth
7.62% -0.82% 25.66% 68.56% -69.59% -23.59% -157.86% 46.42% 13.74% -17.38% -16.23%
EPS Growth
7.62% -0.82% 52.57% 68.56% 49.60% -23.59% -157.86% 90.26% 13.74% 62.27% 97.06%
Operating Cash Flow Growth
-61.72% 17.51% 14.09% 42.66% 5.68% 34.29% -209.84% 9.56% 16.67% -9.52% 11.04%
Free Cash Flow Firm Growth
-26.18% 44.62% -33.37% 18.55% 37.07% 111.11% -5,278.64% 57.01% 44.10% -13.87% -20.18%
Invested Capital Growth
179.53% -715.39% 38.56% 108.31% -95.78% -64,563.71% 56.16% 105.88% -622.28% -133.92% -75.00%
Revenue Q/Q Growth
-17.21% 62.46% 1,500.39% -49.02% 0.00% -100.00% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
1.69% -5.80% 10.68% 38.16% -26.00% 23.92% -0.31% -50.73% 5.74% -2.66% -49.55%
EBIT Q/Q Growth
1.54% -4.60% 10.83% 37.50% -25.53% 24.08% -0.31% -50.75% 5.75% -2.66% -49.54%
NOPAT Q/Q Growth
1.49% -6.73% 20.27% 5.32% -3.95% -19.50% -0.91% 1.12% 5.04% -1.56% -57.60%
Net Income Q/Q Growth
3.41% -3.09% 11.72% 37.82% -25.88% 22.43% 0.47% -50.63% 5.74% -2.65% -49.48%
EPS Q/Q Growth
3.41% -3.09% 4.76% 37.82% -70.40% 22.43% 0.47% -70.06% 5.74% -8.75% 80.00%
Operating Cash Flow Q/Q Growth
-2.26% -1.17% 11.80% 7.55% -5.69% 9.51% -11.36% -1.91% 4.79% 2.91% -7.57%
Free Cash Flow Firm Q/Q Growth
-10.58% 5.52% 18.13% -25.13% 14.89% 109.74% -81.61% 27.40% 18.88% 9.00% -47.76%
Invested Capital Q/Q Growth
2,116.54% -11.47% -26.54% 121.03% 104.31% -895.97% 68.05% 115.30% 1.03% -87.80% -118.07%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00%
EBITDA Margin
-172,230.53% -118,842.48% -5,857.00% -1,847.89% -53,700.16% 0.00% 0.00% 0.00% -4,912.40% 0.00% 0.00%
Operating Margin
-183,896.78% -127,027.23% -5,118.12% -3,176.71% -56,071.81% 0.00% 0.00% 0.00% -5,228.00% 0.00% 0.00%
EBIT Margin
-183,903.66% -123,058.90% -5,991.23% -1,919.35% -54,634.68% 0.00% 0.00% 0.00% -4,914.00% 0.00% 0.00%
Profit (Net Income) Margin
-200,671.03% -129,721.85% -6,025.38% -1,894.08% -54,252.64% 0.00% 0.00% 0.00% -4,920.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.11% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
109.12% 105.41% 100.57% 98.58% 99.30% 102.33% 108.65% 100.09% 100.12% 100.08% 100.06%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% -4,418.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% -4,375.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 4,268.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-184.28% -258.62% -157.88% -67.62% -149.46% 1,046.32% -20,012.03% -143.72% -103.40% -153.55% -24.52%
Cash Return on Invested Capital (CROIC)
-1,831.15% 0.00% 0.00% -3,506.32% -4,234.36% 0.00% 0.00% -7,781.90% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-85.54% -106.47% -85.38% -46.27% -117.89% 0.00% 0.00% 0.00% -82.41% 0.00% 0.00%
Return on Assets (ROA)
-93.33% -112.24% -85.87% -45.66% -117.07% 0.00% 0.00% 0.00% -82.51% 0.00% 0.00%
Return on Common Equity (ROCE)
-184.28% -258.46% -157.72% -67.53% -149.30% 6,087.00% 695,079.50% -143.69% -103.38% -153.52% -24.52%
Return on Equity Simple (ROE_SIMPLE)
-420.83% -185.99% -183.98% -81.40% -162.93% 62.17% -361.38% -114.27% -108.72% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-13 -14 -9.31 -5.78 -6.04 -6.51 -29 -11 -9.15 -10 -13
NOPAT Margin
-128,727.75% -88,919.06% -3,582.68% -2,223.70% -39,250.27% 0.00% 0.00% 0.00% -3,659.60% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-65.45% -64.35% -45.13% 9.82% -42.37% -147.95% 50.91% -28.57% -25.65% -36.67% -5.79%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -79.76% -137.38% -9.76%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
62,682.80% 46,147.99% 2,104.23% 1,753.56% 29,788.48% 0.00% 0.00% 0.00% 2,480.80% 0.00% 0.00%
R&D to Revenue
121,313.99% 80,979.24% 3,113.88% 1,523.15% 26,383.33% 0.00% 0.00% 0.00% 2,757.20% 0.00% 0.00%
Operating Expenses to Revenue
183,996.78% 127,127.23% 5,218.12% 3,276.71% 56,171.81% 0.00% 0.00% 0.00% 5,328.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-19 -20 -16 -4.99 -8.41 -10 -24 -14 -12 -14 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-18 -19 -15 -4.80 -8.27 -10 -24 -14 -12 -14 -17
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
4,948.46 721.21 61.26 18.88 0.75 0.00 2.40 0.64 0.48 0.29 2.71
Price to Tangible Book Value (P/TBV)
6,361.69 790.33 68.36 21.61 0.86 0.00 2.40 0.64 0.48 0.29 2.71
Price to Revenue (P/Rev)
2,359,639.86 502,563.68 2,003.94 438.46 248.65 0.00 0.00 0.00 21.75 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
29,423.10 0.00 0.00 412.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
2,359,243.20 501,550.45 1,959.08 416.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 38.38 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.63 0.33 0.00 0.00 0.00 -0.09 0.00 0.01 0.01 0.01 0.00
Long-Term Debt to Equity
0.72 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.01 -1.26 -1.42 -1.20 -0.98 2.61 -39.61 -1.15 -1.03 -1.17 -1.05
Leverage Ratio
1.97 2.30 1.84 1.48 1.28 -4.87 58.39 1.42 1.25 1.33 1.06
Compound Leverage Factor
2.15 2.43 1.85 1.46 1.27 -4.98 63.44 1.43 1.25 1.33 1.06
Debt to Total Capital
61.99% 24.74% 0.02% 0.00% 0.00% -10.46% 0.00% 0.70% 1.38% 1.04% 0.05%
Short-Term Debt to Total Capital
34.78% 24.62% 0.00% 0.00% 0.00% -8.99% 0.00% 0.70% 1.38% 1.04% 0.05%
Long-Term Debt to Total Capital
27.22% 0.12% 0.02% 0.00% 0.00% -1.46% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.07% 0.12% 0.17% 0.04% 0.00% 0.03% 0.02% 0.02% 0.03% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% -147.86% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
38.01% 75.20% 99.86% 99.83% 99.96% 258.32% 99.97% 99.28% 98.61% 98.93% 99.94%
Debt to EBITDA
-0.45 -0.19 0.00 0.00 0.00 -0.07 0.00 -0.01 -0.01 -0.01 0.00
Net Debt to EBITDA
0.23 0.85 0.77 0.00 0.00 0.00 0.00 0.86 1.00 0.68 7.95
Long-Term Debt to EBITDA
-0.20 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
-0.60 -0.26 0.00 0.00 0.00 -0.10 0.00 -0.01 -0.02 -0.01 -0.01
Net Debt to NOPAT
0.31 1.14 1.25 0.00 0.00 0.01 0.00 1.12 1.34 0.94 10.55
Long-Term Debt to NOPAT
-0.27 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
1,457.67 420.39 34.44 1.66 -49.03 -44.53 -14.13 -10.32 -12.86 -20.68 41.48
Noncontrolling Interest Sharing Ratio
0.00% 0.06% 0.10% 0.14% 0.11% -481.75% 3,573.31% 0.02% 0.02% 0.02% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.09 2.85 8.22 6.19 4.61 0.11 4.61 4.89 5.15 3.24 28.95
Quick Ratio
1.91 2.76 7.95 5.85 4.19 0.10 4.20 4.11 4.81 3.03 28.77
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-15 -8.47 -11 -9.20 -5.79 0.64 -33 -14 -8.00 -9.11 -11
Operating Cash Flow to CapEx
-10,740.03% -15,920.51% -117,675.31% 0.00% 0.00% -79,466.67% 0.00% -133,600.00% -278,325.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-8.42 -7.42 -71.02 -1,195.37 -649.20 2.74 -15.72 -1,101.44 -533.60 -759.53 -1,095.32
Operating Cash Flow to Interest Expense
-10.42 -13.68 -84.34 -999.28 -813.42 -20.29 -6.97 -1,027.69 -742.20 -1,016.08 -1,084.70
Operating Cash Flow Less CapEx to Interest Expense
-10.52 -13.77 -84.42 -999.05 -813.42 -20.31 -6.97 -1,028.46 -742.47 -1,016.08 -1,084.70
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.01 0.02 0.00 0.00 0.00 0.00 0.02 0.00 0.00
Accounts Receivable Turnover
0.08 0.32 1.20 0.71 0.08 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.03 0.05 1.18 1.98 0.23 0.00 0.00 0.00 25.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
4,604.81 1,133.33 305.45 512.11 4,493.85 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
4,604.81 1,133.33 305.45 512.11 4,493.85 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
0.84 -5.14 -3.16 0.26 0.01 -7.14 -3.13 0.18 -0.96 -2.25 -3.93
Invested Capital Turnover
-0.10 -0.01 -0.06 -0.18 0.11 0.00 0.00 0.00 -0.64 0.00 0.00
Increase / (Decrease) in Invested Capital
1.89 -5.98 1.98 3.42 -0.25 -7.15 4.01 3.31 -1.15 -1.29 -1.69
Enterprise Value (EV)
24,576 8,148 509 108 -1.29 25 7.15 -4.28 -6.83 -7.55 217
Market Capitalization
24,580 8,165 521 114 3.83 15 18 8.02 5.44 2.19 350
Book Value per Share
$0.05 $0.10 $0.56 $0.33 $1.33 ($0.96) $0.54 $0.16 $1.23 $5.63 $0.87
Tangible Book Value per Share
$0.04 $0.09 $0.50 $0.29 $1.15 ($0.96) $0.54 $0.16 $1.23 $5.63 $0.87
Total Capital
13 15 8.52 6.05 5.13 -6.43 7.37 13 11 7.57 129
Total Debt
8.10 3.72 0.00 0.00 0.00 0.67 0.00 0.09 0.16 0.08 0.07
Total Long-Term Debt
3.56 0.02 0.00 0.00 0.00 0.09 0.00 0.00 0.00 0.00 0.00
Net Debt
-4.13 -16 -12 -5.79 -5.11 -0.04 -10 -12 -12 -9.74 -133
Capital Expenditures (CapEx)
0.18 0.10 0.01 -0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.68 -2.92 -0.74 -0.33 -0.69 -7.32 -1.49 -0.57 -1.53 -2.48 -3.73
Debt-free Net Working Capital (DFNWC)
12 17 11 5.46 4.42 -6.61 9.01 12 11 7.34 130
Net Working Capital (NWC)
7.01 14 11 5.46 4.42 -7.19 9.01 12 11 7.26 130
Net Nonoperating Expense (NNE)
7.49 6.63 6.35 -0.86 2.31 3.81 -2.68 3.26 3.15 4.04 4.14
Net Nonoperating Obligations (NNO)
-4.13 -16 -12 -5.79 -5.11 -0.04 -10 -12 -12 -9.74 -133
Total Depreciation and Amortization (D&A)
1.22 0.68 0.35 0.19 0.14 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
-6,558.45% -17,960.54% -284.89% -126.88% -4,500.41% 0.00% 0.00% 0.00% -612.80% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
110,884.05% 106,346.66% 4,205.47% 2,098.93% 28,726.28% 0.00% 0.00% 0.00% 4,360.00% 0.00% 0.00%
Net Working Capital to Revenue
67,251.72% 83,536.21% 4,205.47% 2,098.93% 28,726.28% 0.00% 0.00% 0.00% 4,296.80% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($1,035.00) ($11,385.00) ($5,400.00) ($1,440.00) ($17,100.00) ($5,265.00) ($2,145.00) ($247.95) ($27.00) ($10.19) ($0.30)
Adjusted Weighted Average Basic Shares Outstanding
20.45K 2.46K 3.37K 4.05K 2.10K 3.84K 12.41K 58.69K 456.01K 1.42M 55.67M
Adjusted Diluted Earnings per Share
($1,035.00) ($11,385.00) ($5,400.00) ($1,440.00) ($17,100.00) ($5,265.00) ($2,542.50) ($247.95) ($27.00) ($10.19) ($0.30)
Adjusted Weighted Average Diluted Shares Outstanding
20.45K 2.46K 3.37K 4.05K 2.10K 3.84K 12.46K 58.69K 456.01K 1.42M 55.67M
Adjusted Basic & Diluted Earnings per Share
($1,035.00) ($11,385.00) ($5,400.00) ($1,440.00) ($17,100.00) ($5,265.00) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
20.19K 1.86K 2.90K 3.37K 488.00 3.08K 24.31K 300.27K 851.40K 4.40M 165.88M
Normalized Net Operating Profit after Tax (NOPAT)
-13 -14 -9.31 -5.78 -6.04 -6.51 -29 -11 -8.99 -10 -13
Normalized NOPAT Margin
-128,727.75% -88,919.06% -3,582.68% -2,223.70% -39,250.27% 0.00% 0.00% 0.00% -3,596.60% 0.00% 0.00%
Pre Tax Income Margin
-200,671.03% -129,721.85% -6,025.38% -1,892.01% -54,252.64% 0.00% 0.00% 0.00% -4,920.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-10.55 -17.52 -97.93 -648.26 -942.88 -42.92 -11.56 -1,095.92 -819.00 -1,202.17 -1,677.10
NOPAT to Interest Expense
-7.38 -12.66 -58.56 -751.05 -677.38 -27.69 -13.83 -846.52 -609.93 -866.78 -1,263.92
EBIT Less CapEx to Interest Expense
-10.65 -17.60 -98.00 -648.04 -942.88 -42.95 -11.56 -1,096.69 -819.27 -1,202.17 -1,677.10
NOPAT Less CapEx to Interest Expense
-7.48 -12.74 -58.63 -750.83 -677.38 -27.72 -13.83 -847.28 -610.20 -866.78 -1,263.92
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-0.22% 0.00% 0.00% 0.00% 0.00% 0.00% -0.25% -4.40% -5.02% -3.99% -3.68%

Quarterly Metrics And Ratios for Palisade Bio

This table displays calculated financial ratios and metrics derived from Palisade Bio's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
12,771,015.00 937,562.00 1,184,487.00 1,329,516.00 4,396,646.00 4,795,646.00 9,119,152.00 149,003,210.00 165,884,817.00 173,579,670.00 174,270,558.00
DEI Adjusted Shares Outstanding
851,401.00 937,562.00 1,184,487.00 1,329,516.00 4,396,646.00 4,795,646.00 9,119,152.00 149,003,210.00 165,884,817.00 173,579,670.00 174,270,558.00
DEI Earnings Per Adjusted Shares Outstanding
-4.14 -4.35 -2.94 8.34 -0.51 -0.58 -0.31 0.05 -0.06 -0.06 -0.08
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-50.71% -20.34% 2.98% -12.61% 36.79% 31.79% 17.76% -166.30% -330.83% -280.22% -410.94%
EBIT Growth
-50.68% -20.30% 2.98% -12.61% 36.78% 31.78% 17.75% -166.30% -330.64% -280.09% -410.76%
NOPAT Growth
-45.24% -16.68% 4.90% -7.23% 37.11% 32.49% 18.68% -195.12% -365.28% -311.47% -437.30%
Net Income Growth
-50.73% -20.25% 3.03% -12.55% 36.77% 31.76% 17.75% -166.12% -330.49% -279.81% -409.87%
EPS Growth
-50.73% 58.13% 68.56% 220.09% 89.76% 82.53% 83.62% -98.21% 89.36% 91.38% 81.58%
Operating Cash Flow Growth
9.81% -59.12% -17.69% 13.29% 26.64% 48.07% -13.41% -32.05% -66.74% -318.44% -230.96%
Free Cash Flow Firm Growth
77.68% 16.35% 20.42% -1.66% -2.30% 73.04% 37.16% -390.62% -346.95% -1,189.38% -727.31%
Invested Capital Growth
-369.33% -449.48% -23.28% -133.92% -56.68% -135.36% -50.71% -75.00% -177.30% -37.90% 50.44%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Q/Q Growth
-18.81% -15.66% 14.64% 3.99% 33.31% -24.82% -2.91% -210.87% -7.89% -10.16% -38.29%
EBIT Q/Q Growth
-18.84% -15.66% 14.64% 4.02% 33.28% -24.81% -2.91% -210.76% -7.89% -10.16% -38.29%
NOPAT Q/Q Growth
-16.46% -14.65% 14.68% 5.87% 31.70% -23.07% -2.78% -241.58% -7.68% -8.84% -34.21%
Net Income Q/Q Growth
-18.71% -15.68% 14.53% 4.10% 33.31% -24.84% -3.02% -210.29% -7.88% -10.15% -38.29%
EPS Q/Q Growth
-18.71% 27.67% 30.12% 437.50% -106.00% -23.40% 34.48% 136.84% -135.71% 0.00% -40.00%
Operating Cash Flow Q/Q Growth
-15.80% -10.03% 10.46% 24.00% 2.02% 22.12% -95.54% 11.51% -23.73% -95.45% -54.66%
Free Cash Flow Firm Q/Q Growth
14.46% -129.31% -9.80% 52.80% 13.92% 39.56% -155.90% -268.51% 21.58% -74.36% -64.19%
Invested Capital Q/Q Growth
-26.12% 12.95% -13.46% -87.80% 15.52% -30.75% 27.35% -118.07% -33.86% 34.98% 73.89%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,114.80% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,339.60% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,114.80% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,114.80% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.04% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
100.03% 100.05% 100.17% 100.09% 100.00% 100.07% 100.17% 100.02% 100.01% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-113.28% -110.09% -135.96% -153.55% -170.72% -188.48% -228.64% -24.52% -36.40% -51.37% -75.56%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -15.78% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -15.78% 0.00%
Return on Common Equity (ROCE)
-113.26% -110.08% -135.93% -153.52% -170.67% -188.42% -228.54% -24.52% -36.40% -51.36% -75.56%
Return on Equity Simple (ROE_SIMPLE)
-134.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.57 -2.95 -2.52 -2.37 -1.62 -1.99 -2.05 -6.99 -7.52 -8.19 -11
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,637.72% 0.00%
Net Nonoperating Expense Percent (NNEP)
-7.78% -8.39% -8.50% -8.87% -6.62% -9.86% -12.83% -2.67% -2.97% -3.66% -6.14%
Return On Investment Capital (ROIC_SIMPLE)
-25.55% -28.62% -36.75% -31.27% -30.33% -67.83% -59.75% -5.40% -5.91% -6.73% -9.77%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 959.60% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,480.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,439.60% 0.00%
Earnings before Interest and Taxes (EBIT)
-3.53 -4.08 -3.48 -3.34 -2.23 -2.78 -2.86 -8.90 -9.60 -11 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-3.53 -4.08 -3.48 -3.34 -2.23 -2.78 -2.86 -8.90 -9.60 -11 -15
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.51 0.42 0.64 0.29 0.56 1.25 2.44 2.71 2.28 2.98 2.09
Price to Tangible Book Value (P/TBV)
0.51 0.42 0.64 0.29 0.56 1.25 2.44 2.71 2.28 2.98 2.09
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 725.56 470.53
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 2.31 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 43.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 475.22 243.31
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.04 0.04 0.01 0.00 0.12 0.07 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.03 -1.05 -1.10 -1.17 -1.20 -1.28 -1.31 -1.05 -1.05 -1.05 -1.02
Leverage Ratio
1.17 1.21 1.28 1.33 1.35 1.55 1.66 1.06 1.07 1.08 1.09
Compound Leverage Factor
1.17 1.21 1.28 1.33 1.35 1.56 1.66 1.06 1.07 1.08 1.09
Debt to Total Capital
0.00% 3.39% 3.43% 1.04% 0.00% 10.70% 6.16% 0.05% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 3.39% 3.43% 1.04% 0.00% 10.70% 6.16% 0.05% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.02% 0.02% 0.03% 0.03% 0.04% 0.07% 0.06% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
99.98% 96.59% 96.54% 98.93% 99.96% 89.23% 93.78% 99.94% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 -0.02 -0.02 -0.01 0.00 -0.03 -0.02 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.78 0.56 0.68 0.00 0.43 0.45 7.95 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 -0.03 -0.02 -0.01 0.00 -0.04 -0.03 -0.01 0.00 0.00 0.00
Net Debt to NOPAT
0.00 1.06 0.76 0.94 0.00 0.60 0.63 10.55 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-12.67 -13.34 -19.39 -17.32 -23.14 -30.05 -28.40 41.67 28.47 38.08 21.63
Noncontrolling Interest Sharing Ratio
0.02% 0.02% 0.02% 0.02% 0.03% 0.03% 0.04% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.87 4.34 3.31 3.24 2.84 1.62 1.96 28.95 23.71 24.26 20.16
Quick Ratio
4.57 4.00 3.00 3.03 2.60 1.36 1.50 28.77 23.60 23.96 19.50
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-0.91 -2.08 -2.29 -1.08 -0.93 -0.56 -1.44 -5.30 -4.16 -7.25 -12
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-909.10 -1,042.35 -381.52 -360.13 0.00 -281.05 -287.68 -2,650.35 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-3,180.00 -1,749.50 -522.17 -793.67 0.00 -908.50 -710.60 -1,572.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-3,180.00 -1,749.50 -522.17 -793.67 0.00 -908.50 -710.60 -1,572.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-1.21 -1.06 -1.20 -2.25 -1.90 -2.48 -1.80 -3.93 -5.27 -3.42 -0.89
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.17 -0.37
Increase / (Decrease) in Invested Capital
-1.66 -0.86 -0.23 -1.29 -0.69 -1.43 -0.61 -1.69 -3.37 -0.94 0.91
Enterprise Value (EV)
-6.18 -6.78 -3.60 -7.55 -4.23 -1.84 2.83 217 158 238 122
Market Capitalization
5.10 4.22 4.20 2.19 2.99 3.26 7.84 350 290 363 235
Book Value per Share
$0.79 $10.61 $5.58 $5.63 $1.21 $0.55 $0.35 $0.87 $0.77 $0.70 $0.65
Tangible Book Value per Share
$0.79 $10.61 $5.58 $5.63 $1.21 $0.55 $0.35 $0.87 $0.77 $0.70 $0.65
Total Capital
10 10 6.84 7.57 5.33 2.93 3.42 129 127 122 112
Total Debt
0.00 0.35 0.24 0.08 0.00 0.31 0.21 0.07 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-11 -11 -7.81 -9.74 -7.23 -5.10 -5.02 -133 -133 -125 -114
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.73 -1.53 -1.62 -2.48 -2.12 -2.63 -1.67 -3.73 -5.01 -3.16 -1.97
Debt-free Net Working Capital (DFNWC)
9.55 9.83 6.42 7.34 5.11 2.79 3.56 130 128 122 112
Net Working Capital (NWC)
9.55 9.48 6.19 7.26 5.11 2.48 3.35 130 128 122 112
Net Nonoperating Expense (NNE)
0.96 1.13 0.97 0.98 0.61 0.79 0.82 1.91 2.08 2.39 3.63
Net Nonoperating Obligations (NNO)
-11 -11 -7.81 -9.74 -7.23 -5.10 -5.02 -133 -133 -125 -113
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -631.60% -393.20%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24,402.80% 22,329.40%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24,402.80% 22,329.40%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($4.59) ($3.32) ($2.32) $7.83 ($0.47) ($0.58) ($0.38) $0.14 ($0.05) ($0.05) ($0.07)
Adjusted Weighted Average Basic Shares Outstanding
768.14K 1.23M 1.50M 1.42M 4.80M 4.80M 7.47M 55.67M 209.66M 211.38M 212.03M
Adjusted Diluted Earnings per Share
($4.59) ($3.32) ($2.32) $7.83 ($0.47) ($0.58) ($0.38) $0.14 ($0.05) ($0.05) ($0.07)
Adjusted Weighted Average Diluted Shares Outstanding
768.14K 1.23M 1.50M 1.42M 4.80M 4.80M 7.47M 55.67M 209.66M 211.38M 212.03M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $7.83 $0.00 $0.00 $0.00 $0.14 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
937.56K 1.18M 1.33M 4.40M 4.80M 9.12M 149.00M 165.88M 173.58M 174.27M 179.28M
Normalized Net Operating Profit after Tax (NOPAT)
-2.57 -2.95 -2.52 -2.37 -1.62 -1.99 -2.05 -6.99 -7.52 -8.19 -11
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,637.72% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,114.80% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-3,526.00 -2,039.00 -580.17 -1,113.67 0.00 -1,391.00 -572.60 -4,448.50 0.00 0.00 0.00
NOPAT to Interest Expense
-2,571.10 -1,473.85 -419.18 -789.13 0.00 -995.05 -409.08 -3,493.35 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-3,526.00 -2,039.00 -580.17 -1,113.67 0.00 -1,391.00 -572.60 -4,448.50 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-2,571.10 -1,473.85 -419.18 -789.13 0.00 -995.05 -409.08 -3,493.35 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-1.51% -3.20% -3.60% -3.99% -5.74% -3.09% -2.65% -3.68% -2.01% -1.61% -1.18%

Financials Breakdown Chart

Key Financial Trends

Palisade Bio’s Q2 2026 statements show a company with substantially improved liquidity, but continuing heavy operating losses and significant shareholder dilution. The company reported its first meaningful quarterly revenue in the provided period, although the business remains far from profitability.

  • Cash reserves remain strong: Cash and equivalents totaled $125.2 million at June 30, 2026. Despite a $7.5 million quarterly decline, liquidity is substantially higher than the $5.2 million reported in Q3 2025.
  • Balance sheet leverage is low: Total liabilities were $5.6 million, including no short-term debt. With $127.3 million of current assets and $5.2 million of current liabilities, Palisade had an approximate current ratio of 24.2.
  • Revenue began to emerge: Q2 2026 operating revenue was $500,000, compared with no revenue in the prior quarters shown. Because reported cost of revenue was zero, the company recorded $500,000 of gross profit, although this level of revenue is not yet sufficient to support operations.
  • Other income continues to provide some support: Net other income was $1.1 million in Q2 2026, helping reduce the operating loss. This income is not a substitute for recurring product revenue and may fluctuate.
  • Cash usage is accelerating: Net cash used in operating activities increased from $3.9 million in Q1 2026 to $7.6 million in Q2. At the Q2 pace, the company would use approximately $30 million annually before considering changes in spending or additional financing.
  • Financing has been the primary source of liquidity: Palisade raised approximately $128.2 million through common equity issuance in Q4 2025, compared with only $20,000 of common-stock issuance in Q2 2026. The large financing explains much of the improvement in cash rather than internally generated cash flow.
  • Operating losses remain substantial: Q2 operating expenses reached $12.2 million, consisting of $7.4 million in research and development and $4.8 million in selling, general and administrative costs. The company reported a $10.6 million net loss, compared with a $9.6 million loss in Q1 2026.
  • Expenses have risen sharply from historical levels: Quarterly operating expenses were generally between $2.3 million and $4.2 million during the 2024 and early 2025 periods provided. The increase to $12.2 million in Q2 2026 indicates a significantly higher cash-burn structure.
  • Shareholder dilution is a major concern: Weighted-average basic shares outstanding increased from approximately 4.8 million in Q1 2025 to 211.4 million in Q2 2026. Future equity financing could further dilute existing shareholders if operating losses continue.
  • Accumulated losses remain large: Retained earnings were negative $172.9 million at June 30, 2026, reflecting the company’s long history of losses. Palisade has not yet demonstrated that its new revenue can offset research, development and corporate expenses.

Overall, Palisade Bio has a substantially stronger liquidity position than it had in 2024 and early 2025, and its low debt burden reduces near-term balance-sheet risk. However, the latest quarter also showed worsening operating cash burn, higher expenses, a $10.6 million net loss and extensive dilution. Investors should focus on whether revenue can grow consistently and whether management can reduce the company’s quarterly cash requirements.

11/17/26 11:58 PM ETAI Generated. May Contain Errors.

Palisade Bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Palisade Bio's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

In the past 10 years, Palisade Bio's net income has ranged from -$26.62 million in 2021 to -$4.92 million in 2018, and is currently -$16.78 million as of their latest financial filing in 2025. See where experts think Palisade Bio is headed by visiting Palisade Bio's forecast page.

Palisade Bio's total operating income in 2025 was -$18.06 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $18.06 million

Over the last 10 years, Palisade Bio's total revenue changed from $10.42 thousand in 2015 to $0.00 in 2025, a change of -100.0%.

In the past 12 quarters, Palisade Bio's cash and equivalents has ranged from $5.23 million in Q3 2025 to $132.63 million in Q1 2026, and is currently $113.61 million as of their latest financial filing in Q3 2026.

Palisade Bio had total debt of $71 thousand at the end of 2025, a 10.1% decrease from 2024, and a 99.1% decrease since 2015.

Over the last 10 years, Palisade Bio's book value per share changed from 0.05 in 2015 to 0.87 in 2025, a change of 1,505.0%.



Financial statements for NASDAQ:PALI last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners